Tag Archives: Ahu Demir

TrovaGene (TROV) Receives a Buy from Noble Financial

Noble Financial analyst Ahu Demir maintained a Buy rating on TrovaGene (TROV – Research Report) yesterday and set a price target of $23.00. The company’s shares closed last Monday at $1.34, close to its 52-week low of $1.21. According to

Noble Financial Sticks to Its Buy Rating for TherapeuticsMD (TXMD)

Noble Financial analyst Ahu Demir maintained a Buy rating on TherapeuticsMD (TXMD – Research Report) yesterday. The company’s shares closed last Monday at $3.78. According to TipRanks.com, Demir is a 3-star analyst with an average return of 5.8% and a

Noble Financial Sticks to Their Buy Rating for TrovaGene (TROV)

In a report released yesterday, Ahu Demir from Noble Financial reiterated a Buy rating on TrovaGene (TROV – Research Report), with a price target of $23. The company’s shares closed last Monday at $1.92, close to its 52-week low of

Noble Financial Reaffirms Their Buy Rating on Electrocore Llc (ECOR)

Noble Financial analyst Ahu Demir maintained a Buy rating on Electrocore Llc (ECOR – Research Report) yesterday and set a price target of $11. The company’s shares closed last Monday at $1.39, close to its 52-week low of $1.23. According

TherapeuticsMD (TXMD) Receives a Buy from Noble Financial

In a report issued on August 9, Ahu Demir from Noble Financial maintained a Buy rating on TherapeuticsMD (TXMD – Research Report), with a price target of $13. The company’s shares closed on Friday at $3.10. According to TipRanks.com, Demir

Noble Financial Sticks to Their Buy Rating for Dyadic International (DYAI)

In a report released today, Ahu Demir from Noble Financial reiterated a Buy rating on Dyadic International (DYAI – Research Report), with a price target of $9. The company’s shares closed on Friday at $5.82. According to TipRanks.com, Demir is